Cargando…
Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET
PURPOSE: This study aimed to investigate the uptake characteristics of (18)F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas. MATERIALS AND METHODS: Patients w...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613590/ https://www.ncbi.nlm.nih.gov/pubmed/37219717 http://dx.doi.org/10.1007/s11604-023-01450-x |
_version_ | 1785128861579608064 |
---|---|
author | Wang, Yang Fushimi, Yasutaka Arakawa, Yoshiki Shimizu, Yoichi Sano, Kohei Sakata, Akihiko Nakajima, Satoshi Okuchi, Sachi Hinoda, Takuya Oshima, Sonoko Otani, Sayo Ishimori, Takayoshi Tanji, Masahiro Mineharu, Yohei Yoshida, Kazumichi Nakamoto, Yuji |
author_facet | Wang, Yang Fushimi, Yasutaka Arakawa, Yoshiki Shimizu, Yoichi Sano, Kohei Sakata, Akihiko Nakajima, Satoshi Okuchi, Sachi Hinoda, Takuya Oshima, Sonoko Otani, Sayo Ishimori, Takayoshi Tanji, Masahiro Mineharu, Yohei Yoshida, Kazumichi Nakamoto, Yuji |
author_sort | Wang, Yang |
collection | PubMed |
description | PURPOSE: This study aimed to investigate the uptake characteristics of (18)F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas. MATERIALS AND METHODS: Patients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering (18)F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUV(max) (rSUV(max)) and SUV(mean) (rSUV(mean)), 10th percentile of ADC (ADC(10pct)), mean ADC (ADC(mean)) were measured in HIA and CET, respectively. RESULTS: rSUV(mean) in HIA and rSUV(mean) in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUV(mean) in HIA and ADC(10pct) in CET, that of rSUV(max) and ADC(10pct) in CET, that of rSUV(mean) in HIA and ADC(mean) in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUV(max), rSUV(mean) in HIA and rSUV(mean) in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUV(mean) in HIA and ADC(10pct) in CET was able to differentiate IDH-mutant (AUC 0.81). CONCLUSION: PET using (18)F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11604-023-01450-x. |
format | Online Article Text |
id | pubmed-10613590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-106135902023-10-31 Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET Wang, Yang Fushimi, Yasutaka Arakawa, Yoshiki Shimizu, Yoichi Sano, Kohei Sakata, Akihiko Nakajima, Satoshi Okuchi, Sachi Hinoda, Takuya Oshima, Sonoko Otani, Sayo Ishimori, Takayoshi Tanji, Masahiro Mineharu, Yohei Yoshida, Kazumichi Nakamoto, Yuji Jpn J Radiol Original Article PURPOSE: This study aimed to investigate the uptake characteristics of (18)F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas. MATERIALS AND METHODS: Patients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering (18)F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUV(max) (rSUV(max)) and SUV(mean) (rSUV(mean)), 10th percentile of ADC (ADC(10pct)), mean ADC (ADC(mean)) were measured in HIA and CET, respectively. RESULTS: rSUV(mean) in HIA and rSUV(mean) in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUV(mean) in HIA and ADC(10pct) in CET, that of rSUV(max) and ADC(10pct) in CET, that of rSUV(mean) in HIA and ADC(mean) in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUV(max), rSUV(mean) in HIA and rSUV(mean) in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUV(mean) in HIA and ADC(10pct) in CET was able to differentiate IDH-mutant (AUC 0.81). CONCLUSION: PET using (18)F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11604-023-01450-x. Springer Nature Singapore 2023-05-23 2023 /pmc/articles/PMC10613590/ /pubmed/37219717 http://dx.doi.org/10.1007/s11604-023-01450-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Wang, Yang Fushimi, Yasutaka Arakawa, Yoshiki Shimizu, Yoichi Sano, Kohei Sakata, Akihiko Nakajima, Satoshi Okuchi, Sachi Hinoda, Takuya Oshima, Sonoko Otani, Sayo Ishimori, Takayoshi Tanji, Masahiro Mineharu, Yohei Yoshida, Kazumichi Nakamoto, Yuji Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET |
title | Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET |
title_full | Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET |
title_fullStr | Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET |
title_full_unstemmed | Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET |
title_short | Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET |
title_sort | evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18f-fluoromisonidazole pet |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613590/ https://www.ncbi.nlm.nih.gov/pubmed/37219717 http://dx.doi.org/10.1007/s11604-023-01450-x |
work_keys_str_mv | AT wangyang evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT fushimiyasutaka evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT arakawayoshiki evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT shimizuyoichi evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT sanokohei evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT sakataakihiko evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT nakajimasatoshi evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT okuchisachi evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT hinodatakuya evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT oshimasonoko evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT otanisayo evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT ishimoritakayoshi evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT tanjimasahiro evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT mineharuyohei evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT yoshidakazumichi evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet AT nakamotoyuji evaluationofisocitratedehydrogenasemutationin2021worldhealthorganizationclassificationgrade3and4gliomaadulttypediffusegliomaswith18ffluoromisonidazolepet |